BLA 125274 · Ipsen Biopharm LTD
Dysport
Abobotulinumtoxina · Injection · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelOrphanLast checked: Nov 20, 2026Latest source record: Sep 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Apr 29, 2009
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1,077
324 Phase 3, 72 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Abobotulinumtoxina" as an intervention, any sponsor and status, largest first.
- Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Revance Therapeutics, Inc.Industry
NCT03004248 · 2,691 participants · Start Dec 9, 2016 · Primary completion Oct 17, 2018
Drug: Botulinum Toxins, Type A · For: Glabellar Frown Lines
Sites: Birmingham, Alabama; Beverly Hills, California; Encinitas, California · 61 sites in all
- Using Botox to Treat Patients With Idiopathic ClubfootStatus unknown
University of British ColumbiaAcademic, hospital or other
NCT00474032 · 2,000 participants (planned) · Start Mar 2003 · Primary completion Mar 2023
Drug: Botulinum Toxin (Type A) injection (10 U/Kg) · For: Clubfoot
Sites: Vancouver, Canada
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018700 · 997 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown LinesPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01189760 · 917 participants · Start Sep 1, 2010 · Primary completion Mar 1, 2011
Drug: onabotulinumtoxinA 24 U; onabotulinumtoxinA 44 U and 1 more · For: Facial Rhytides; Crow's Feet Lines; Glabellar Lines
Sites: Newport Beach, California; Vancouver, Canada; Antibes, France · 4 sites in all
- Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinencePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00915525 · 829 participants · Start Feb 1, 2010 · Primary completion Aug 5, 2014
Drug: botulinum toxin Type A · For: Overactive Bladder; Urinary Incontinence
Sites: Newport Beach, California; Ghent, Belgium; Victoria, Canada · 8 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018713 · 808 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Chronic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 111 sites in all
- Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown LinesPivotal-lookingCompleted
Merz Pharmaceuticals GmbHIndustry
NCT00512135 · 801 participants · Start Jun 18, 2007 · Primary completion Dec 28, 2009
Drug: IncobotulinumtoxinA (Xeomin) (20 units) · For: Glabellar Lines
Sites: Los Angeles, California; Englewood, Colorado; Aventura, Florida · 25 sites in all
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsPivotal-lookingCompleted
AEON Biopharma, Inc.Industry
NCT04845178 · 797 participants · Start Mar 1, 2021 · Primary completion Jun 19, 2024
Drug: ABP-450; Placebo · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dysport (Abobotulinumtoxina)
2024 spending
$3.3M
Beneficiaries
844
2,140 claims
Per beneficiary
$3,967
$769.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,344,262 |
| 2021 | $1,687,663 |
| 2022 | $2,229,776 |
| 2023 | $2,633,467 |
| 2024 | $3,348,256 |
Part B: Dysport (Abobotulinumtoxina) · HCPCS J0586
2024 spending
$14.2M
Beneficiaries
3,906
9,664 claims
Per beneficiary
$3,625
2024 ASP limit $8.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,170,607 |
| 2021 | $9,797,355 |
| 2022 | $11,079,936 |
| 2023 | $12,370,684 |
| 2024 | $14,159,679 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of technical aspects and clinical outcomes of botulinum toxin prior to abdominal wall reconstruction.
Timmer AS, Claessen JJM, Atema JJ, et al. · Hernia 2021 · Meta-Analysis, Systematic Review
- Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.
Walter U, Albrecht P, Carr W, et al. · Eur J Neurol 2025 · Systematic Review, Meta-Analysis
- Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB, Duarte GS, Marques RE, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
Esquenazi A, Wein TH, Verduzco-Gutierrez M, et al. · Adv Ther 2026 · Randomized Controlled Trial, Multicenter Study
- Botulinum toxin type A versus anticholinergics for cervical dystonia.
Rodrigues FB, Duarte GS, Castelão M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Ipsen Biopharm LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.